Author

T. F. Westbrook

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Arnal-Estape· 1 shared A. Balabaki· 1 shared C. Hamor· 1 shared C. M. Perou· 1 shared C. Montemayor-Garcia· 1 shared D. Acosta· 1 shared D. Nguyen· 1 shared E. B. Kabotyanski· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Arnal-Estape

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation

Q. Yan, J. F.-Y. Chen, W. Cai, H. Chen, E. Wingrove, S. Kurley, L. H. Chan, M. Zhang, A. Arnal-Estape, M. Zhao, A. Balabaki, W. Li, X. Yu, Y. Dou, Y. Liu, , D. Nguyen

This study identifies WDR5 as an epigenetic regulator that promotes breast cancer growth and metastasis through KMT2-independent translation regulation, suggesting therapeutic strategies targeting WDR5.

bioRxiv · Mar 30, 2022 · PreprintCancer Biology

Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics

Y. Gao, E. B. Kabotyanski, E. Villegas, J. H. Shepherd, D. Acosta, C. Hamor, T. Sun, C. Montemayor-Garcia, X. He, L. E. Dobrolecki, T. F. Westbrook, M. T. Lewis, S. G. Hilsenbeck, X. H.- F. Zhang, C. M. Perou, J. M. Rosen

This study shows PLK2 loss predicts better response to PLK1 inhibitors in triple-negative breast cancer and suggests PLK2 as a biomarker for treatment response.

bioRxiv · Jun 16, 2021Cancer Biology